Analyst Ratings For Adaptive Biotechnologies Corp (NASDAQ:ADPT)
Today, BTIG Research initiated coverage on Adaptive Biotechnologies Corp (NASDAQ:ADPT) with a Buy with a price target of $46.00.
There are 6 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Adaptive Biotechnologies Corp (NASDAQ:ADPT) is Buy with a consensus target price of $43.00 per share, a potential 7.10% upside.
Some recent analyst ratings include
- 7/23/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Buy ➝ Buy rating and $46.00 price target
- 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Outperform ➝ Outperform rating
- 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Outperform ➝ Outperform rating
- 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Buy ➝ Buy rating and $47.00 price target
- 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Buy ➝ Buy rating and $45.00 price target
- 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Overweight rating and $45.00 price target
- 7/22/2019-Adaptive Biotechnologies Corp (NASDAQ:ADPT) has coverage initiated with a Neutral ➝ Neutral rating and $32.00 price target
Recent Trading Activity for Adaptive Biotechnologies Corp (NASDAQ:ADPT)
Shares of Adaptive Biotechnologies Corp closed the previous trading session at 40.46 up +1.19 3.03% with 39.59 shares trading hands.
